Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Adamas Pharma (NQ: ADMS )

4.890 USD -0.240 (-4.68%)
Streaming Delayed Price Updated: 11:36 AM EST, Mar 4, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Adamas Pharma

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Adamas Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced... 
From Business Wire News Releases
Adamas Pharmaceuticals Announces Pricing of Follow-on Public Offering
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced... 
From Business Wire News Releases
Adamas Pharmaceuticals Announces Launch of Follow-on Public Offering
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced... 
From Business Wire News Releases
Adamas Reports Fourth Quarter and Full Year 2020 Financial Results
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported... 
From Business Wire News Releases
Adamas to Present at Upcoming Healthcare Conferences
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced... 
From Business Wire News Releases
Adamas to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call on February 23, 2021
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2020 financial results on Tuesday, February 23, 2021, after market close.... 
From Business Wire News Releases
Adamas Announces FDA Approval for Second Indication for GOCOVRI® as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it... 
From Business Wire News Releases
Adamas Announces Settlement of Patent Litigation with Zydus
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today... 
From Business Wire News Releases
Adamas Provides Preliminary Fourth Quarter and Full Year 2020 Total Revenues and Key Business Drivers for 2021
From GlobeNewswire News Releases
Adamas to Present at Upcoming ICR Conference
From GlobeNewswire News Releases
Adamas Completes Acquisition of OSMOLEX ER®
Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition 
From GlobeNewswire News Releases
Adamas to Present at Upcoming H.C. Wainwright Conference
From GlobeNewswire News Releases
Adamas Announces New Employment Inducement Grant
From GlobeNewswire News Releases
Adamas Announces Agreement to Amend Royalty-Backed Loan Agreement with HealthCare Royalty Partners
Amended terms will provide added flexibility to help drive the growth of the Company 
From GlobeNewswire News Releases
Adamas Announces Agreement to Settle Patent Litigation with Osmotica
As part of this agreement Adamas will acquire the global rights to OSMOLEX ER® 
From GlobeNewswire News Releases
Adamas to Present at Upcoming Evercore ISI Conference
From GlobeNewswire News Releases
Adamas announces changes to its Board of Directors with the appointment of Spyros Papapetropoulos and the retirement of Ivan Lieberburg
From GlobeNewswire News Releases
Adamas to Present at Upcoming Piper Sandler Conference
From GlobeNewswire News Releases
Adamas Announces New Employment Inducement Grant
From GlobeNewswire News Releases
Adamas Reports Third Quarter 2020 Financial Results
From GlobeNewswire News Releases
Adamas announces settlement agreement of previously disclosed class action litigation
From GlobeNewswire News Releases
Adamas to Announce Third Quarter 2020 Financial Results and Host Conference Call on November 5, 2020
From GlobeNewswire News Releases
Adamas Announces New Employment Inducement Grant
From GlobeNewswire News Releases
Adamas appoints new Chief Medical Officer, Adrian Quartel, MD
From GlobeNewswire News Releases
Adamas Announces New Employment Inducement Grant
From GlobeNewswire News Releases
Adamas presents new post-hoc data analysis for GOCOVRI® in Parkinson’s disease patients with dyskinesia at the 2020 Movement Disorder Society Virtual Congress
From GlobeNewswire News Releases
Adamas to Present at Upcoming HC Wainwright Conference
From GlobeNewswire News Releases
Adamas Appoints Anna Richo to Board of Directors
From GlobeNewswire News Releases
Adamas Announces New Employment Inducement Grant
From GlobeNewswire News Releases
Stocks That Surged Higher Over The Past Week: $ZSAN $ADMS $EXPI
Tags The Market Signal
From The Market Signal
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.